Skip to main content

Table 3 Base Case Value and Range of Utilities Extracted from Literatures

From: Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

Variables Base case value Range
Compensated cirrhosis without progressive HCC52 0.76 0.76–0.80
Compensated cirrhosis with progressive HCC52 0.68 0.60–0.68
Decompensated cirrhosis53 0.57 0.46–0.68
\